Electronic ISSN 2287-0237

VOLUME

DABIGATRAN, FEARS IN DOCTORS’ MINDS.

FEBRUARY 2018 - VOL.14 | LETTER TO THE EDITOR
  1. US Food and Drug Administration. FDA Drug Safety Communication: Safety review of post-market reports of serious bleedingevents with the anticoagulant Pradaxa (dabigatran etexilate mesylate).2012 (Accessed September 13, 2017 at https://www.fda.gov/drugs/drugsafety/ucm282724.htm).
  2. Australian Government, Department of Health and Aging, Therapeutic Goods Administration. Dabigatran (Pradaxa) and risk ofbleeding: Information for health professionals. 2013 (Accessed September 13, 2017 at https://www.tga.gov.au/alert/dabigatranpradaxa-and-risk-bleeding-information-health-professionals).
  3. The Japanese Ministry of Health, Labor, and Welfare. Safety advisory of the potential for adverse events with dabigatran, November3, 2011. (Accessed September 13, 2012 at http://www.theheart.org/article/1264365.do).
  4. Connolly SJ, Ezekowitz MD, Yusuf S, et.al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2009;361:1139-51.
  5. Camm AJ1, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: anupdate of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the EuropeanHeart Rhythm Association. Eur Heart J 2012;33(21):2719-47.
  6. Tomimori H, Yamamura N, Adachi T, et al. Pharmacokinetics, safety and pharmacodynamics after multiple oral doses of dabigatranetexilate capsule (110 mg and 150 mg b.i.d., 7 days) in healthy Japanese and Caucasian male subjects: An open label study. Studyno. 1160.61. Report no. U06-3420. Boehringer Ingelheim Internal Report, 2006.
  7. Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. N Engl J Med 2017;377:431-41.
SEARCH VOLUME & NUMBER
GO
RECENT VOLUME & NUMBER